Saturday, October 31, 2026

Starbucks Stock Bullish Momentum With A 1% Rise So Far Today

ViaNews Editorial Team

December 15, 2020

Starbucks Stock Bullish Momentum With A 1% Rise So Far Today
Shares of Starbucks jumped 1.14% to $104.50 at 13:22 EST on Tuesday, following yesterday's upward trend. The Nasdaq Stock Market is jumping 0.67% to $12,523.00, following yesterday's upward trend, This seems, up to now, a somewhat positive trend trading session today. Starbucks's last close was $103.32, 1.52% under its 52-week high of $106.09.

Starbucks's Sales

Starbucks's sales growth is a negative 1.9% for the ongoing quarter and 11.9% for the next. The company's growth estimates for the current quarter is a negative 29.1% and positive 87.5% for the next.

Starbucks's Revenue

Year-on-year quarterly revenue growth declined by 8.1%, now sitting on 23.52B for the twelve trailing months.

Starbucks's Stock Top and Bottom Yearly Value

Starbucks's stock is valued at $104.50 at 13:22 EST, below its 52-week high of $106.09 and way above its 52-week low of $50.02.

Starbucks's Moving Average

Starbucks's value is above its 50-day moving average of $95.87 and way higher than its 200-day moving average of $84.45.

Previous days news about Starbucks

Some like it cold: Starbucks sold $1 billion in chilled drinks in last 3 years. According to MarketWatch on Thu Dec 10, ""Cold has grown by nearly 45% the past four years," said Rosalind Brewer, Starbucks' chief operating officer, during a Wednesday investor event, according to a FactSet transcript."

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com